About Atalanta Therapeutics
Atalanta Therapeutics is a company based in Boston (United States) founded in 2019 by Neal Aronin, Craig Mello, and Anastasia Khvorova. It operates as a HealthTech. Atalanta Therapeutics has raised $207 million across 2 funding rounds from investors including Mirae Asset, Biogen and EQT. Atalanta Therapeutics offers products and services including di-siRNA Therapy. Atalanta Therapeutics operates in a competitive market with competitors including Alnylam, Avidity Biosciences, Silence Therapeutics, Sirnaomics and Dicerna Pharmaceuticals, among others.
- Headquarter Boston, United States
- Founders Neal Aronin, Craig Mello, Anastasia Khvorova
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Atalanta Therapeutics
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$207 M (USD)
in 2 rounds
-
Latest Funding Round
$97 M (USD), Series B
Jan 28, 2025
-
Investors
Mirae Asset
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atalanta Therapeutics
Atalanta Therapeutics offers a comprehensive portfolio of products and services, including di-siRNA Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative RNA interference therapy for neurological diseases developed.
Unlock access to complete
Unlock access to complete
Funding Insights of Atalanta Therapeutics
Atalanta Therapeutics has successfully raised a total of $207M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $97 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $97.0M
-
First Round
First Round
(11 Jan 2021)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series B - Atalanta Therapeutics | Valuation | EQT , Sanofi Ventures | |
| Jan, 2021 | Amount | Series A - Atalanta Therapeutics | Valuation | F-Prime Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Atalanta Therapeutics
Atalanta Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Mirae Asset, Biogen and EQT. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by abrdn's private equity fund.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Atalanta Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Atalanta Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Atalanta Therapeutics Comparisons
Competitors of Atalanta Therapeutics
Atalanta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Avidity Biosciences, Silence Therapeutics, Sirnaomics and Dicerna Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
RNA therapeutics for hematology and cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Drugs are developed using RNA interference technology platform.
|
|
| domain | founded_year | HQ Location |
Therapeutics for intractable diseases are developed via gene silencing.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Atalanta Therapeutics
Frequently Asked Questions about Atalanta Therapeutics
When was Atalanta Therapeutics founded?
Atalanta Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Atalanta Therapeutics located?
Atalanta Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Atalanta Therapeutics?
Alicia Secor is the current CEO of Atalanta Therapeutics.
Is Atalanta Therapeutics a funded company?
Atalanta Therapeutics is a funded company, having raised a total of $207M across 2 funding rounds to date. The company's 1st funding round was a Series A of $110M, raised on Jan 11, 2021.
What does Atalanta Therapeutics do?
Atalanta Therapeutics is engaged in the development of innovative RNA interference therapies targeting neurological diseases. The company is built on groundbreaking discoveries aimed at halting disease progression at its source. Solutions are primarily directed towards conditions like Huntingtons disease and KCNT1-related epilepsy. Their proprietary di-siRNA approach is utilized to create powerful therapeutic interventions. The focus remains on addressing urgent global needs in the central nervous system (CNS) disease sector.
Who are the top competitors of Atalanta Therapeutics?
Atalanta Therapeutics's top competitors include Alnylam, Avidity Biosciences and Silence Therapeutics.
What products or services does Atalanta Therapeutics offer?
Atalanta Therapeutics offers di-siRNA Therapy.
Who are Atalanta Therapeutics's investors?
Atalanta Therapeutics has 9 investors. Key investors include Mirae Asset, Biogen, EQT, abrdn, and Genentech.